Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: P53 status has a strong impact on prognosis

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 1, 2004, Pages 231-236

  Suzuki, Yoshiyuki ^a,b   Nakano, Takashi ^a,b   Kato, Shingo ^a   Ohno, Tatsuya ^a   Tsujii, Hirohiko ^a   Oka, Kuniyuki ^a,c  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Mito Saiseikai General Hospital   (Japan)

Author keywords

Adenocarcinoma; Cyclin D1; p27; p53; Uterine cervix

Indexed keywords

DISEASE-FREE SURVIVAL RATE; PROTEIN EXPRESSION;

CELLS; CHEMOTHERAPY; DISEASES; PROTEINS; SURGERY; TUMORS;

RADIOTHERAPY;

CELL CYCLE PROTEIN; CYCLIN D1; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ADENOSQUAMOUS; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 4444357353     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.02.032     Document Type: Article

References (49)

1. Brand E., Berek J.S., Hacker N.F. Controversies in the management of cervical adenocarcinoma. Obstet Gynecol. 71:1988;261-269
2. Kleine W., Rau K., Schwoeorer D., et al. Prognosis of the adenocarcinoma of the cervix uteri A comparative study. Gynecol Oncol. 35:1989;145-149
3. Eifel P.J., Morris M., Oswald M.J., et al. Adenocarcinoma of the uterine cervix Prognosis and patterns of failure in 367 cases. Cancer. 65:1990;2507-2514
4. Leminen A., Paavonen J., Forss M., et al. Adenocarcinoma of the uterine cervix. Cancer. 65:1990;53-59
5. 1 control in mammalian cells. J Cell Sci Suppl 1994;18:69-73
6. Suzuki Y., Nakano T., Arai T., et al. Progesterone receptor is a favorable prognostic factor of radiation therapy for adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 47:2000;1229-1234
7. Tsuda H., Jiko K., Tsugane S., et al. Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix. Jpn J Cancer Res. 86:1995;1049-1053
8. Kihara T., Tsuda H., Teshima S., et al. Prognostic significance of the overexpression of c-erbB2 protein in adenocarcinoma of the cervix. Cancer. 73:1994;148-153
9. Lu X., Toki T., Konishi I., et al. Expression of p21WAF1/Cip1 in adenocarcinoma of the uterine cervix. Cancer. 82:1998;2409-2417
10. Silcocks P.B.S., Thornton-Jones H., Murphy M. Squamous and adenocarcinoma of the uterine cervix A comparison using routine data. Br J Cancer. 55:1987;321-325
11. Chen R.J., Chang D.Y., Yen M.L., et al. Prognostic factors of primary adenocarcinoma of the uterine cervix. Gynecol Oncol. 69:1998;157-164
12. International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in carcinoma of the uterus, vagina and ovary. 1979;FIGO, Radiumhemmet, Sweden. vol 16
13. Poulsen H.E., Taylor C.W., Sobin L.H. Histological typing of female genital tract tumors. 1975;World Health Organization, Geneva, Switzerland. No. 13
14. Arai T., Nakano T., Morita S., et al. High dose rate remote after-loading intracavitary radiation therapy for cancer of the uterine cervix. Cancer. 69:1992;175-180
15. Nakano T., Arai T., Morita S., et al. Radiation therapy alone for adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 32:1995;1331-1336
16. Jain D., Srinivvasan R., Patel F.D., et al. Evaluation of p53 and bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol. 88:2003;22-28
17. Shariat S.F., Kim J., Raptidis G., et al. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 61:2003;1140-1145
18. Liu X.P., Kawauchi S., Oga A., et al. Combined examination of p27(Kip1), p21(Waf1/Cip1) and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology. 39:2001;603-610
19. Alfsen G.C., Reed W., Sandstad B., et al. The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix. Cancer. 98:2003;1880-1889
20. 1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder. Br J Cancer. 80:1999;1175-1184
21. Nagasawa S., Onda M., Sasajima K., et al. Cyclin D1 overexpression as a prognostic factor in patients with esophageal carcinoma. J Surg Oncol. 78:2001;208-214
22. 1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174
23. Lane D.P. A death in the life of p53. Nature. 362:1993;786-787
24. Mitsudomi T., Hamajima N., Ogawa M., et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer. Clin Cancer Res. 6:2000;4055-4063
25. Rahko E., Blanco G., Soini Y., et al. A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur J Cancer. 39:2003;447-453
26. Lorenzo-Romero J.G., Salinas-Sanchez A.S., Gimenez-Bachs J.M., et al. Prognostic implications of p53 gene mutations in bladder tumors. J Urol. 169:2003;492-499
27. Oka K., Suzuki Y., Nakano T. p27 and p53 expression in cervical squamous cell carcinoma patients treated with radiation therapy alone Radiotherapeutic effect and prognosis. Cancer. 88:2000;2766-2773
28. Roth J.A., Nguyen D., Lawrence D.D., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 2:1996;985-991
29. Swisher S.G., Roth J.A., Timmons T., et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 91:1999;763-771
30. Xiong Y., Hannon G.J., Zhang H., et al. p21 is a universal inhibitor of cyclin kinase. Nature. 366:1993;701-704
31. Schmider A., Gee C., Friedmann W., et al. p21(WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecol Oncol. 77:2000;237-242
32. Zirbes T.K., Baldus S.E., Moenig S.P., et al. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer. 89:2000;14-18
33. Shoji T., Tanaka F., Takata T., et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol. 20:2002;3865-3871
34. Niibe Y., Nakano T., Ohno T., et al. Relationship between p21/WAF-1/CIP-1 and apoptosis in cervical cancer during radiation therapy. Int J Radiat Oncol Biol Phys. 44:1999;297-303
35. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:1994;59-66
36. Mizumatsu S., Tamiya T., Ono Y., et al. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma. Clin Cancer Res. 5:1999;551-557
37. Porter P.L., Malone K.E., Heagerty P.J., et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 3:1997;222-225
38. Catzavelos C., Bhattacharya N., Ung Y.C., et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein Prognostic implications in primary breast cancer. Nat Med. 3:1997;227-230
39. Tan P., Cady B., Wanner M., et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 57:1997;1259-1263
40. Loda M., Cukor B., Tam S.W., et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 3:1997;231-234
41. Mori M., Mimori K., Shiraishi T., et al. p27 expression and gastric carcinoma. Nat Med. 3:1997;593
42. Mineta H., Miura K., Suzuki I., et al. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer. 85:1999;1011-1017
43. Tsihlias J., Kapusta L.R., DeBoer G., et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58:1998;542-548
44. Kirka R.M., Haapasalo H.K., Kalimo H., et al. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer. 97:2003;644-648
45. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330
46. Wagner U., Suess K., Luginbuhl T., et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol. 188:1999;44-50
47. Coupland S.E., Anastassiou G., Stang A., et al. The prognostic value of cyclin D1, P53, and MDM2 protein expression in uveal melanoma. J Pathol. 191:2000;120-126
48. Yoo S.S., Carter D., Turner B.C., et al. Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. Int J Cancer. 90:2000;22-28
49. Sallinen S.L., Sallinen P.K., Kononen J.T., et al. Cyclin D1 expression in astrocytomas is associated with cell proliferation activity and patient prognosis. J Pathol. 188:1999;289-293